Report Company Directory

Venus Medtech (Hangzhou) (H)

• Asian Daily: China - MicroPort CardioFlow Medtech: FY21 TAVR sales volume guide down due to 2H21 COVID resurgence . Maintain OUTPERFORM by Credit Suisse
• Asian Daily: China - Venus Medtech: Cardiovalve acquisition expanding TMVR/TTVR product portfolio with earliest launch in 2026+. Maintain OUTPERFORM by Credit Suisse
• 6826.HK: Shanghai Haohai Biological Technology - A laggard play; initiate with OUTPERFORM by Credit Suisse
• 300957.SZ: Yunnan Botanee Bio-Technology - Best domestic dermocosmetic brand fairly valued; initiate with NEUTRAL rating by Credit Suisse
• 688363.SS: Bloomage Biotechnology - Fully integrated aesthetics leader with multi-engines; initiate with OUTPERFORM by Credit Suisse
• 6699.HK: Angelalign Technology - Strong fundamentals fully priced in; initiate with UNDERPERFORM rating by Credit Suisse
• China Aesthetics Sector: Aesthetics in the limelight by Credit Suisse
• 2216.HK: Broncus Medical - Big fish in not-so-small pond: Leading interventional pulmonary device player by Credit Suisse

Venus Metals Corp. Ltd.

• 1 director bought by SmartInsider
• Ford Equity International Rating and Forecast Report by Ford Equity Research

VENUS PIPES & TUBES LIMITED

Venus Remedies

• Venus Remedies Ltd: 1 director by SmartInsider
• Ford Equity International Rating and Forecast Report by Ford Equity Research

VENUS UNIVERSAL LTD